Sue has served as Ardelyx’s Chief Financial Officer since October 2025, bringing more than 30 years of experience in corporate finance, strategic planning, investor relations and operations across a variety of therapeutic areas and stages of development within the healthcare industry. She has a demonstrated track record of driving organizational transformation, building financial strength and driving sustainable growth across commercial and development-stage products. Prior to joining Ardelyx, Sue enjoyed a 28-year career at Johnson & Johnson (J&J) where she led multiple finance organizations in areas such as supply chain, innovation, commercial, business development, investor relations, acquisitions and divestitures, and finance planning and analysis. In her most recent role as Vice President and Chief Financial Officer of J&J Innovative Medicine North America, Sue led a number of strategic initiatives that resulted in greater efficiencies, effectiveness and funding for growth. Sue was also a critical partner during the acquisition of two significant deals which resulted in successful commercial launches.
Sue is a Certified Public Accountant in the Commonwealth of Pennsylvania and a Certified Management Accountant. She was also a Board Member of the Institute of Management Accountants (IMA) where she provided oversight and strategy planning for the IMA and its members. Sue was named a Top 25 CFO in Biotech by Business & Investing and was recently honored by her alma mater, La Salle University, with their highest leadership award for contributions to the university, their students and the community.
She earned a Bachelor of Science in Accounting from La Salle University and a Master of Business Administration from Villanova University. Sue began her career as an auditor at Arthur Andersen, LLP in Philadelphia.
What is Susan Hohenleitner's net worth?
The estimated net worth of Susan Hohenleitner is at least $1.43 million as of February 20th, 2026. Hohenleitner owns 230,533 shares of Ardelyx stock worth more than $1,426,999 as of March 6th. This net worth estimate does not reflect any other assets that Hohenleitner may own. Learn More about Susan Hohenleitner's net worth.
How do I contact Susan Hohenleitner?
Has Susan Hohenleitner been buying or selling shares of Ardelyx?
During the past quarter, Susan Hohenleitner has sold $11,893.05 of Ardelyx stock. Most recently, Susan Hohenleitner sold 2,033 shares of the business's stock in a transaction on Friday, February 20th. The shares were sold at an average price of $5.85, for a transaction totalling $11,893.05. Following the completion of the sale, the chief financial officer now directly owns 230,533 shares of the company's stock, valued at $1,348,618.05. Learn More on Susan Hohenleitner's trading history.
Who are Ardelyx's active insiders?
Ardelyx's insider roster includes John Bishop (Insider), Robert Blanks (Insider), James Brady (Insider), Eric Foster (Chief Commercial Officer), Elizabeth Grammer (Insider), Susan Hohenleitner (CFO), Jeffrey Jacobs (Insider), Mike Kelliher (Insider), David Mott (Director), Michael Raab (CEO), Joseph Reilly (Insider), Justin Renz (Chief Financial & Operations Officer), Susan Rodriguez (Insider), David Rosenbaum (Insider), Scott Sandell (Major Shareholder), and Laura Williams (Chief Medical Officer). Learn More on Ardelyx's active insiders.
Are insiders buying or selling shares of Ardelyx?
In the last year, Ardelyx insiders bought shares 5 times. They purchased a total of 1,214,710 shares worth more than $5,349,075.66. In the last year, insiders at the biopharmaceutical company sold shares 29 times. They sold a total of 575,834 shares worth more than $3,146,127.53. The most recent insider tranaction occured on February, 20th when Director David M Mott bought 333,333 shares worth more than $1,946,664.72. Insiders at Ardelyx own 4.8% of the company.
Learn More about insider trades at Ardelyx. Information on this page was last updated on 2/20/2026.
